Literature DB >> 11976381

Impairment of hippocampal CA1 heterosynaptic transformation and spatial memory by beta-amyloid(25-35).

Miao-Kun Sun1, Daniel L Alkon.   

Abstract

In Alzheimer's disease, the cholinergic damage (reduced neurotransmission) and cognitive impairment occur long before beta-amyloid (Abeta) plaque formation. It has not been established whether the link between soluble Abeta and cholinergic functions contributes to synaptic dysfunction that underlies the cognitive impairment. Here, we report that Abeta(25-35), an active form of Abeta, inhibited long-term synaptic modification that depends on the associative activation of cholinergic and GABAergic inputs when bilaterally injected intracerebroventricularly (icv; 200 microg/site). The Abeta microinjections did not affect single-pulse-evoked glutamatergic and GABAergic synaptic transmission onto the hippocampal CA1 pyramidal cells, while cholinergic intracellular theta; was dramatically reduced by the Abeta(25-35) injection. Spatial memory of the water maze task was also impaired by the bilateral icv Abeta(25-35) injections, while bilateral microinjections of the same dose of Abeta(35-25) was ineffective in affecting the long-term synaptic modification evoked by associative activation of cholinergic and GABAergic inputs, the cholinergic intracellular theta;, or producing memory impairments. Thus restoring the synaptic plasticity involved in this associative activation of cholinergic and GABAergic inputs may offer an important therapeutic target in the treatment of early Abeta-induced memory decline.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11976381     DOI: 10.1152/jn.00230.2001

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  15 in total

Review 1.  Synaptic plasticity in animal models of early Alzheimer's disease.

Authors:  Michael J Rowan; Igor Klyubin; William K Cullen; Roger Anwyl
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-04-29       Impact factor: 6.237

2.  Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.

Authors:  Yu-Fang Cheng; Chuang Wang; Huan-Bing Lin; Yun-Feng Li; Ying Huang; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2010-07-17       Impact factor: 4.530

3.  Studies of the effects of central administration of beta-amyloid peptide (25-35): pathomorphological changes in the Hippocampus and impairment of spatial memory.

Authors:  M Yu Stepanichev; I M Zdobnova; I I Zarubenko; N A Lazareva; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2006-01

4.  Transient reduction of spontaneous neuronal network activity by sublethal amyloid beta (1-42) peptide concentrations.

Authors:  Philipp Görtz; Jessica Opatz; Mario Siebler; Susanne Aileen Funke; Dieter Willbold; Christian Lange-Asschenfeldt
Journal:  J Neural Transm (Vienna)       Date:  2009-02-13       Impact factor: 3.575

5.  Memory deficits and neurochemical changes induced by C-reactive protein in rats: implication in Alzheimer's disease.

Authors:  Huan-Bing Lin; Xue-Mei Yang; Tie-Jun Li; Yu-Fang Cheng; Han-Ting Zhang; Jiang-Ping Xu
Journal:  Psychopharmacology (Berl)       Date:  2009-03-05       Impact factor: 4.530

6.  A structural basis for enhancement of long-term associative memory in single dendritic spines regulated by PKC.

Authors:  Jarin Hongpaisan; Daniel L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-04       Impact factor: 11.205

7.  A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts.

Authors:  Tapan K Khan; Thomas J Nelson; Vishal A Verma; Paul A Wender; Daniel L Alkon
Journal:  Neurobiol Dis       Date:  2009-02-20       Impact factor: 5.996

Review 8.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

9.  Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model.

Authors:  Aynun N Begum; Fusheng Yang; Edmond Teng; Shuxin Hu; Mychica R Jones; Emily R Rosario; Walter Beech; Beverly Hudspeth; Oliver J Ubeda; Greg M Cole; Sally A Frautschy
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

10.  The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy.

Authors:  F Peña; Ai Gutiérrez-Lerma; R Quiroz-Baez; C Arias
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.